Multibagger Shares

About Manish Goel

SEBI Registered Investment Adviser • Chartered Accountant

422 Articles Published

Manish Goel is a Chartered Accountant and the Founder of Multibagger Securities Research & Advisory Pvt. Ltd. (SEBI Registered Investment Adviser, INA100007736). A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

May 17, 2026

Hero image: dark blue page with white 'Board Meeting Frequency' title, green subtitle, and a green timeline across FY21–FY25 showing milestones: Compliance, Disclosure, Audit clean, Board change, All boxes.

Board Meeting Frequency: SEBI LODR Regulation 17(2) and the Forensic Governance Engagement Test

Board meeting frequency is the cheapest forensic governance signal hidden in every Indian annual report. SEBI LODR Reg 17(2) sets the floor at 4, best-practice boards meet 8-12 times, and Titan Biotech FY25 illustrates the disciplined end with 14 meetings sitting alongside a fortress balance sheet.

May 17, 2026

Infographic: The Klarman Doctrine title with a horizontal bar chart of FY20–FY25 values, ending with a green FY25 bar at 22.

The Klarman Doctrine: Seth Klarman’s 1991 ‘Margin of Safety’ Three-Pillar Architecture — Why Absolute Returns, Bottom-Up Bargain Hunting, and Risk Aversion Define the Real Value Investor’s Edge

Seth Klarman's 1991 'Margin of Safety' rebuilt value investing on three pillars: absolute returns, bottom-up bargain hunting, and risk aversion. How Titan Biotech FY25's audited numbers illustrate all three.

May 16, 2026

Infographic-style hero showing four investor mindsets: Lucky (left, gray), Confused (left, light gray), Disciplined Investor (right, green), and Bias-Trapped (right, orange).

Myopic Loss Aversion (Benartzi & Thaler 1995): Why Indian Retail Investors Sabotage Long-Term Returns by Checking Portfolios Too Often

Myopic Loss Aversion — Benartzi & Thaler's 1995 Nobel-grade explanation of the equity premium puzzle, applied to Indian retail investors, with Titan Biotech FY25 audited numbers as an anti-MLA corporate-cadence case study.

May 16, 2026

Hero header: Net Debt to EBITDA Ratio with a green accent 'Multibagger Shares' and a subtitle line on a dark blue background.

Net Debt to EBITDA Ratio: The Single Solvency Test Credit Analysts Care About Most

Net Debt to EBITDA is the single ratio professional credit analysts use most when assessing survival odds. This educational deep-dive teaches how to read it, where retail investors misinterpret it, and how Titan Biotech (BSE: 524717) FY25 audited numbers illustrate a -0.75x net-cash fortress reading. Not a buy/sell recommendation.